Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Taiwan Bio, TRACT Therapeutics Partner on Organ Transplant Rejection | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Taiwan Bio, TRACT Therapeutics Partner on Organ Transplant Rejection

Leverages Taiwan Bio’s expertise in cell therapy manufacturing and TRACT Therapeutics’ immune modulating regulatory T cell therapy platform.

By: Anthony Vecchione

Taiwan Bio has entered a partnership with TRACT Therapeutics to advance a cellular therapy for the prevention of allograft rejection in solid organ transplant. The partners will launch a multi-center Phase 2 trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the U.S. and Taiwan.

The partnership leverages Taiwan Bio’s expertise in cellular therapy manufacturing and TRACT Therapeutics’ immune modulating regulatory T cell therapy platform. By combining their strengths, the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced patient outcomes and improved quality of life.

The Phase 2 trial builds on promising Phase 1 results which demonstrated an excellent safety profile and encouraging efficacy signals with TRACT’s autologous Treg product, TregCel. The Phase 2 clinical trial represents the first collaborative effort between the two companies.

“We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options,” said Cyrus Yang, COO of Taiwan Bio. “Together with TRACT Therapeutics, we can bring a synergy of technology and experience to accelerate the development of transformational Treg therapies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics